Allogeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia in first remission
- Authors: Bondarenko SN1, Semenova EV1, Vavilov VN1, Stancheva NV1, Morozova EV1, Alianskiĭ AL1, Babenko EV1, Osipova NÉ1, Zubarovskaia LS1, Afanas'ev BV1
-
Affiliations:
- Институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, СПбГМУ им. акад. И.П. Павлова
- Issue: Vol 85, No 7 (2013)
- Pages: 18-25
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31278
- ID: 31278
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
S N Bondarenko
Институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, СПбГМУ им. акад. И.П. Павлова
Email: dr.sergeybondarenko@gmail.com
E V Semenova
Институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, СПбГМУ им. акад. И.П. Павлова
V N Vavilov
Институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, СПбГМУ им. акад. И.П. Павлова
N V Stancheva
Институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, СПбГМУ им. акад. И.П. Павлова
E V Morozova
Институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, СПбГМУ им. акад. И.П. Павлова
A L Alianskiĭ
Институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, СПбГМУ им. акад. И.П. Павлова
E V Babenko
Институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, СПбГМУ им. акад. И.П. Павлова
N É Osipova
Институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, СПбГМУ им. акад. И.П. Павлова
L S Zubarovskaia
Институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, СПбГМУ им. акад. И.П. Павлова
B V Afanas'ev
Институт детской онкологии, гематологии и трансплантологии им. Р.М. Горбачевой, СПбГМУ им. акад. И.П. Павлова
References
- Yanada M., Matsuo K., Emi N., Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005; 103 (8): 1652-1658.
- Паровичникова Е.Н., Савченко В.Г., Клясова Г.А. и др. Токсичность различных протоколов лечения острых миелоидных лейкозов взрослых: результаты четырех Российских многоцентровых исследований. Тер арх 2010; 7: 5-11.
- Паровичникова Е.Н., Клясова Г.А., Савченко В.Г. и др. Первые результаты лечения острых миелоидных лейкозов взрослых по протоколу ОМЛ-01.10 научно-исследовательской группы гематологических центров России. Тер арх 2012; 7: 10-15.
- Koreth J., Schlenk R., Kopecky K.J. et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301 (22): 2349-2361.
- Krauter J., Heil G., Hoelzer D. et al. Treatment of patients up to 60 years with high risk AML: final results of the AML SHG-Hannover 01/99 Trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2006; 108 (11): Abstr. 433.
- Hubel K., Weingart O., Naumann F. et al. Allogeneic stem cell transplantation in adult patients with acute myeloid leukemia: to transplant or not to transplant? A Systematic review of international guidelines [abstract]. Blood 2009; 114 (22): 577-578. Abstr. 1419.
- Basara N., Schulze A., Wedding U. et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 2009; 23 (4): 635-640.
- Weisdorf D.J., Anasetti C., Antin J.H. et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002; 99 (6): 1971-1977.
- Szydlo R., Goldman J.M., Klein J.P. et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15 (5): 1767-1777.
- Gupta V., Tallman M.S., He W. et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010; 116 (11): 1839-1848.
- Chevallier P., Labopin M., Milpied N. et al. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant 2012; 47: 1442-1447.
- Popat U., de Lima M.J., Saliba R.M. et al. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant 2012; 47: 212-216.
- Byrd J.C., Mrozek K., Dodge R.K. et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100 (13): 4325-4336.
- Grimwade D., Hills R.K., Moorman A.V. et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116 (3): 354-365.
- Грицаев С.В., Мартынкевич И.С., Абдулкадыров К.М. и др. Возраст и кариотип - факторы риска у больных первичным острым миелоидным лейкозом. Клин онкогематол 2010; 4: 359-364.
- Moore J., Nivison-Smith I., Goh K. et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13 (5): 601-607.
- Slovak M.L., Kopecky K.J., Cassileth P.A. et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96 (13): 4075-4083.
- Gyurkocza B., Storb R., Storer B.E. et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 2859-2867.
- Cornelissen J.J., van Putten W.L., Verdonck L.F. et al. Results of a HOVON/SAKK donor versus nodonor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middleaged adults: benefits for whom? Blood 2007; 109 (9): 3658-3666.
- Suciu S., Mandelli F., de Witte T. et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102 (4): 1232-1240.
- Sorror M.L., Giralt S., Sandmaier B.M. et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110 (13): 4606-4613.
- Parimon T., Au D.H., Martin P.J., Chien J.W. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144 (6): 407-414.
- Alyea E.P., Kim H.T., Ho V. et al. Impact of conditioning regimen intensity on outcome of Allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12 (10): 1047-1055.
- Ringden O., Labopin M., Ehninger G. et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27 (27): 4570-4577.
- Khabori M.A., El-Emary M., Xu W. et al. Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation. Bone Marrow Transplant; 2011; 46 (4): 516-522.
- Scott B.L., Sandmaier B.M., Storer B. et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20 (1): 128-135.
![](/img/style/loading.gif)